$HIMS

HIMSHims & Hers Health, Inc. Class A Common Stock

What are people saying about Hims & Hers Health (HIMS) stock on YouTube?

In the past 30 days (As of 11-18), 7 YouTube channels discussed Hims & Hers Health (HIMS) in 10 entries. Most recent: Schwab Network, 2026-11-18.

All takes and content in this window

As of 11-18
11-18
Schwab NetworkPublished 2026-11-18
“Wednesday's Final Takeaways: Gold at 52-Week Lows, Housing Market Mixed”
$HIMSNo side taken
AI summary · HIMS launched Peptides Plus with five combination therapies, which could draw new customers beyond traditional telehealth and add recurring revenue amid rising peptide demand, but none of the initial treatments is FDA-approved and HIMS says safety, effectiveness and dosing are still uncertain; regulatory and scientific risk could materially threaten its growth plans.

Hims&Hers may have missed out on the " hot peptide summer," but there may be a " hot peptide winter" coming, as it launches its new "Peptides Plus" platform offering five combination therapies targeting everything from energy and recovery to cellular health.

This move comes at a time when demand for peptides is increasing, but there is a major obstacle here . None of the initial treatments are approved by the Food and Drug Administration (FDA), and the company itself acknowledges that there is still much to learn about their safety, effectiveness, and appropriate dosages .

11-17
Verified InvestingPublished 2026-11-17
“MAJOR EARNINGS FOR NVIDIA (Silver Bottom?)”
$HIMSBullish
AI summary · HIMS is in a downtrend dating from just before May and, despite decent earnings, it fell and is still falling; the speaker will buy only if it drops to around 18 bucks, seen as a potential support area.

So with the markets generally kind of bouncing a little bit, I'm looking at something that might fall and is a little lower and that's HIMS HIMS. You have a nice downs sloping trend line from all the way back here just before May of this year coming through here coming through here and then finally looking for an area for potential support down here.

11-13
“NVDA Fallout: Where Is the Smart Money Going? | Market Pulse Nov. 13, 2026”
$HIMSBearish
AI summary · HIMS trended up for a long time, but after vaguely recalled account-related problems, it fell for consecutive weeks and gapped down in an exhaustion gap; the speaker concludes it has not recovered.

Let's take a look at the "Hems" company. It's called " [17:18] Hems & Hers Health". Now look at this [17:21] graph, don't you? It is clear that [17:24] this chart has been trending upwards for a long time [17:27] .

They encountered some problems with the accounts or something like that [17:29] . I can't remember. But [17:32] look at all those consecutive weeks of [17:35] decline, until the stock eventually gapped down [17:37] , and that was an exhaustion gap. He [17:39] really couldn't recover, did he?

Parkev Tatevosian, CFAPublished 2026-11-13
“Why Is Hims Stock Crashing, and is it a Buying Opportunity?”
$HIMSBullish
AI summary · HIMS remains a buying opportunity, but his conviction has dropped from moderate to low because expenses grew faster than revenue: G&A nearly doubled to $151.5M, operating income fell to -$66M from $11.8M and operating cash flow dropped to $119M from $239M, making the ~18% drop logical. Despite 49% revenue growth, 13% subscriber growth and 30% higher revenue per subscriber, at $19 the stock is undervalued versus his slightly above $22 fair value and a 25.4 forward P/E.

Hems & Hers announced quarterly financial results that disappointed investors in the stock market. Revenues increased by 49% and subscribers by 13%, but expenses also increased and cash flow decreased significantly.

Investors punished the stock, which fell by about 19 % the day after the company announced these figures. So I wanted to share my rating of Heams & Hers stock, whether I think this represents a buying opportunity after the price drop , and what my estimate of the company's fair value is.

11-10
“Hims & Hers Collapses 30% In a Week”
$HIMSBullish
AI summary · HIMS fell 18% after a disappointing quarter: subscribers fell about 100,000 QoQ, gross margin dropped from 83% to 57% on branded GLP-1 mix, Q4 revenue is guided slightly down and full-year adjusted EBIT guidance was cut. The speaker is not selling and still calls HIMS a great company to own over 5-10 years, based on its higher-priced subscription, TRT and peptide strategy and Costco-like health-subscription model, with management betting on Q1 2027; short-term subscriber growth and competition leave questions, and next quarter's guidance is important.

Shares of his and hers are down 18% in late trading on Tuesday after their company reported earnings on Monday. The investors did not like what they heard from the earnings report.

In a lot of ways, the report was really disappointing. The number of subscribers was down quarter over quarter. Gross margins continued to be under pressure. And management said that they were actually not spending as much to bring in those new customers. That's why growth really slowed.

The Motley FoolPublished 2026-11-10
“Stock Market Update: Rising Rates & Falling Stocks”
$HIMSNo side taken
Schwab NetworkPublished 2026-11-10
“HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus”
$HIMSNo side taken
11-09
Showing 8 / 10 on this page
See this ticker’s full history